Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vaxart reports solid Q1 earnings, progresses in vaccine development

Vaxart's Q1 2024 performance reflects financial stability and progress in vaccine development, particularly with positive Phase I trial results for their norovirus vaccine.
While the company faces challenges in funding, manufacturing, and program prioritization, opportunities lie in advancing COVID-19 vaccine trials and regulatory engagements.
By addressing concerns and leveraging opportunities effectively, Vaxart can strengthen its position in the vaccine market and drive future growth and innovation.

Vaxart reports strong Q3 revenue, advances in COVID and norovirus

Vaxart's Q3 2024 earnings call highlighted revenue from government contracts, progress in COVID, norovirus, and HPV programs, and promising trial data.
The company faces challenges in study enrollment, resource allocation, and regulatory compliance but remains open to collaborations and global vaccine development.
With a cash runway into 2026, Vaxart is well-positioned to leverage market demand for their oral pill vaccine candidates and drive future growth.
Strong performance, constructive FDA feedback, and market opportunities position Vaxart for continued success in vaccine development and partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in March 2004 and is headquartered in South San Francisco, CA.

San Francisco, California--(Newsfile Corp. - August 28, 2020) - Hagens Berman announces that it has filed a class action lawsuit against Vaxart, Inc.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Vaxart (VXRT) Investors: Securities Fraud Class Action Filed, Investors with Losses Encouraged to Contact its Attorneys Now

BENSALEM, Pa.--(BUSINESS WIRE)---- $VXRT #classaction--Deadline Reminder: The Law Offices of Howard G.

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Vaxart, Inc.

NEW YORK, Aug. 28, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Vaxart, Inc.

VXRT Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Vaxart, Inc. Investors of Class Action and Lead Plaintiff Deadline: October 23, 2020

SAN FRANCISCO, Aug. 27, 2020 /PRNewswire/ -- Hagens Berman announces that it has filed a class action lawsuit against Vaxart, Inc.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Vaxart (VXRT) Investors: Firm Files Securities Class Action Complaint, Investors with Losses Encouraged to Contact its Attorneys Now

SOUTH SAN FRANCISCO, Calif., Aug.  27, 2020  (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, today announced the appointment of Karen J. Wilson to its Board of Directors and as chair of its Audit Committee. Ms. Wilson brings more than three decades of finance and leadership experience in the life sciences industry.

Vaxart Appoints Karen J. Wilson to its Board of Directors

Altimmune

Co-Diagnostics

iBio

Novavax

It's not a surprise that all five of these stocks are engaged in the fight against the novel coronavirus.

These 5 Healthcare Stocks Are the Biggest Winners in 2020

SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)---- $VXRT #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Vaxart, Inc. (NASDAQ: VXRT) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between June 25, 2020 and July 25, 2020.

Shareholder Alert: Robbins LLP Announces a Shareholder Has Sued Vaxart, Inc. (VXRT)

San Francisco, California--(Newsfile Corp. - August 26, 2020) -  Hagens Berman announces that it has filed a class action lawsuit against Vaxart, Inc.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Vaxart (VXRT) Investors of Securities Class Action Complaint and Application Deadline, Encourages Investors with Losses to Contact its Attorneys Now

LOS ANGELES--(BUSINESS WIRE)---- $VXRT #classaction--Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Vaxart, Inc. (VXRT) Investors

Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Vaxart, Inc. (VXRT) Investors

LOS ANGELES--(BUSINESS WIRE)---- $VXRT #classaction--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Vaxart, Inc.

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Vaxart, Inc.

Shares of this company, which is making a COVID-19 vaccine in pill form, sell for less than half their peak.

Vaxart Stock: Should You Buy the Dip?

What's the Outlook for Vaxart Stock?

New York, New York--(Newsfile Corp. - August 25, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Vaxart, Inc.

Vaxart Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Vaxart, Inc. To Contact The Firm

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Vaxart, Inc. (NASDAQ: VXRT) between June 25, 2020 to July 25, 2020, inclusive (the “Class Period”).

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Vaxart, Inc. – VXRT

BENSALEM, Pa.--(BUSINESS WIRE)---- $VXRT #classaction--INVESTOR ALERT: Law Offices of Howard G.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Vaxart, Inc.

LOS ANGELES--(BUSINESS WIRE)---- $VXRT #VXRT--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vaxart, Inc.

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vaxart, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $VXRT #VXRT--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vaxart, Inc.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vaxart, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

SAN FRANCISCO--(BUSINESS WIRE)---- $VXRT #NASDAQ--Hagens Berman has filed a class action lawsuit on behalf of investors in Vaxart, Inc. (NASDAQ: VXRT) against the Company and its senior executives

HAGENS BERMAN FILES SECURITIES CLASS ACTION Complaint Against Vaxart (VXRT) and Its Senior Executives

NEW YORK, Aug. 24, 2020 /PRNewswire/ -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international shareholder and consumer rights litigation firm, is investigating whether Vaxart, Inc.

Scott+Scott Attorneys at Law LLP Announces Investigation into Vaxart, Inc. (VXRT)

Inovio Pharmaceuticals

Here's exactly how they could realistically pull it off.

3 Coronavirus Stocks That Could Double by the End of 2020

A potential COVID-19 vaccine in pill form elevated this former penny stock.

Did You Miss Out on the 4900% Gain With Vaxart Stock?

It’s tough to top quadruple-digit growth.

These 3 Surprising Stocks Have Beaten the Market in 2020 -- by a Lot

San Francisco, California--(Newsfile Corp. - August 14, 2020) -  Hagens Berman urges Vaxart, Inc.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Vaxart (VXRT) Investors of Firm's Investigation into Possible Securities Fraud, Encourages Investors with $50K+ Losses and Persons Who May Assist to Contact Its Attorneys Now

SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)---- $VXRT #ClassAction--Shareholder rights law firm Robbins LLP announces it is investigating whether certain officers and directors of Vaxart, Inc. (NASDAQ: VXRT) breached their fiduciary duties and violated federal securities laws.

Shareholder Alert: Robbins LLP Announces It Is Investigating Vaxart, Inc. (VXRT) for Misleading Shareholders

Low-cost prophylactics will be integral to solving the pandemic.

News for Vaxart Stock (VXRT)